Lincosamides Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export

Lincosamides Market Driven by Rising Burden of Gram-Positive Infections

The Lincosamides Market is gaining measurable momentum as healthcare systems confront a sustained rise in gram-positive bacterial infections, particularly those caused by Staphylococcus aureus and Streptococcus species. For instance, hospital-acquired infections account for millions of cases annually across major healthcare economies, with gram-positive organisms representing nearly 60% of reported cases. Lincosamides such as clindamycin remain a frontline therapy in skin and soft tissue infections (SSTIs), bone and joint infections, and anaerobic bacterial infections. The expanding clinical incidence of SSTIs alone—growing at an estimated 4–5% annually in urban hospital networks—directly translates into sustained prescription volumes within the Lincosamides Market.

Datavagyanik highlights that outpatient antibiotic prescriptions for SSTIs have increased steadily over the last five years, particularly in emerging markets where urbanization and diabetes prevalence are rising. For example, diabetic foot infections—strongly associated with gram-positive pathogens—are increasing at over 6% per year globally. This epidemiological shift reinforces structural demand in the Lincosamides Market, as clindamycin remains an essential component of empirical therapy in moderate to severe cases.

Lincosamides Market Strengthened by Expanding Surgical Procedures

The expansion of elective and emergency surgical procedures is another core demand catalyst in the Lincosamides Market. Surgical site infections (SSIs) account for approximately 20% of healthcare-associated infections worldwide. In orthopedic, dental, and gynecological procedures, lincosamides are frequently used as prophylactic or alternative antibiotics, especially in patients allergic to penicillin.

For instance, global surgical volumes are growing at 3–4% annually, with orthopedic procedures increasing even faster due to aging demographics. Hip and knee replacements alone are projected to grow at over 5% per year in developed markets. As a result, prophylactic antibiotic demand in these procedures is expanding proportionally, strengthening the Lincosamides Market. In dental surgeries, where clindamycin is widely prescribed for patients with beta-lactam allergies, procedure volumes are increasing in tandem with cosmetic dentistry growth, which is expanding at approximately 6–7% annually in urban economies.

Lincosamides Market Benefiting from Antibiotic Allergy Prevalence

A significant structural driver in the Lincosamides Market is the rising documentation of beta-lactam allergies. Studies suggest that 8–10% of patients report penicillin allergies, although confirmed cases are lower. Nevertheless, precautionary substitution is common clinical practice. This substitution effect directly benefits the Lincosamides Market, as clindamycin serves as a preferred alternative in multiple treatment guidelines.

For example, in respiratory tract infections and dental abscess management, substitution rates can reach 15–20% in allergy-labeled populations. As electronic health records improve allergy documentation, alternative antibiotic utilization has become more protocol-driven. Datavagyanik indicates that allergy-related antibiotic switching contributes to nearly one-fifth of clindamycin prescriptions in tertiary hospitals, reinforcing steady demand in the Lincosamides Market.

Lincosamides Market Size Expansion Through Emerging Economies

The Lincosamides Market Size is expanding notably across emerging economies where healthcare access and antibiotic penetration are increasing. For instance, healthcare expenditure growth in Asia-Pacific markets has averaged 7–9% annually over the past five years. With broader insurance coverage and hospital infrastructure expansion, antibiotic consumption volumes have increased proportionally.

In countries with growing middle-class populations, outpatient antibiotic usage per capita has risen by 5–6% annually. The Lincosamides Market benefits particularly from urban secondary care centers where empirical antibiotic prescribing patterns dominate. For example, in Southeast Asia and parts of Latin America, clindamycin usage in dermatology and general practice settings has grown alongside rising skin infection incidence linked to tropical climates and population density.

Datavagyanik estimates that emerging markets now contribute over 40% of incremental revenue growth in the Lincosamides Market Size, reflecting a structural shift in geographic demand concentration.

Lincosamides Market Influenced by Antimicrobial Resistance Patterns

Antimicrobial resistance (AMR) dynamics are reshaping prescribing trends and influencing the Lincosamides Market. While resistance to certain antibiotic classes is rising rapidly, lincosamides retain efficacy against specific susceptible strains of MRSA (methicillin-resistant Staphylococcus aureus), particularly in community-acquired infections.

For instance, community-acquired MRSA cases have increased in both developed and developing regions, with annual growth rates between 3–5% in certain metropolitan clusters. In such scenarios, clindamycin remains a treatment option when susceptibility testing confirms effectiveness. This selective yet crucial positioning enhances the therapeutic relevance of the Lincosamides Market.

However, inducible resistance mechanisms, such as MLSB resistance, require careful laboratory screening. This dynamic encourages judicious prescribing rather than indiscriminate use. As stewardship programs become more structured, the Lincosamides Market is increasingly characterized by quality-driven rather than volume-driven growth, stabilizing long-term demand.

Lincosamides Market Trends in Dermatology and Cosmetic Applications

The Lincosamides Market is also benefiting from dermatological applications, particularly in acne treatment. Topical and oral clindamycin formulations are widely used in moderate to severe acne management. Acne prevalence affects nearly 9–10% of the global population, with the highest concentration among adolescents and young adults.

For example, dermatology consultations for acne have grown by approximately 4% annually in urban healthcare networks. The cosmetic dermatology industry, expanding at 6–8% annually, further supports prescription growth. In such settings, combination therapies incorporating clindamycin with benzoyl peroxide are common, supporting diversified product portfolios within the Lincosamides Market.

Datavagyanik notes that dermatology-linked prescriptions contribute significantly to outpatient antibiotic revenue streams, especially in high-income urban populations where aesthetic treatments are routine.

Lincosamides Market Size Supported by Hospital Formularies and Essential Drug Listings

The inclusion of clindamycin in essential medicines lists across multiple countries strengthens baseline demand in the Lincosamides Market. Hospital formularies routinely stock injectable and oral lincosamide formulations due to their broad anaerobic and gram-positive coverage.

For instance, tertiary hospitals typically maintain multiple dosage forms—capsules, injectables, and topical gels—ensuring consistent procurement cycles. Annual hospital antibiotic procurement budgets have expanded at 3–4% per year, directly influencing the Lincosamides Market Size. In large public hospital networks, bulk purchasing agreements stabilize pricing while guaranteeing volume offtake.

Such institutional procurement reduces volatility and anchors predictable revenue streams in the Lincosamides Market, even amid broader antibiotic price pressures.

Lincosamides Market Experiencing Pricing Stability Amid Generic Competition

Generic competition is a defining feature of the Lincosamides Market. Clindamycin has long been off-patent, leading to widespread manufacturing across regions. While this results in pricing pressure, it simultaneously enhances accessibility and volume expansion.

For example, average generic antibiotic prices have declined by 2–3% annually in mature markets due to competitive tendering. However, stable demand offsets margin compression. In emerging markets, price elasticity supports higher volume growth, particularly in private pharmacy channels.

Datavagyanik observes that despite moderate price erosion, the Lincosamides Market maintains balanced revenue performance due to consistent clinical utility. Injectable formulations, often priced higher than oral generics, provide additional margin buffers within hospital segments.

Lincosamides Market Innovation in Formulation and Combination Therapies

Although the Lincosamides Market is largely mature, incremental innovation in formulations sustains differentiation. Extended-release oral formulations, improved topical delivery systems, and fixed-dose combinations are enhancing patient compliance.

For instance, once-daily topical gels improve adherence compared to multiple daily applications. Improved adherence correlates with better clinical outcomes, thereby strengthening prescriber confidence. Combination acne therapies integrating clindamycin demonstrate superior efficacy compared to monotherapy, reinforcing product lifecycle extension strategies within the Lincosamides Market.

Such incremental innovation does not dramatically alter therapeutic positioning but supports brand retention and competitive advantage in crowded generic environments.

Lincosamides Market Outlook Anchored in Steady Clinical Relevance

The Lincosamides Market is not characterized by explosive growth but by resilient, necessity-driven demand. The Lincosamides Market Size continues to expand steadily, supported by infection prevalence, surgical growth, dermatology applications, and antibiotic substitution trends. Annual growth rates in the 3–5% range reflect structural healthcare expansion rather than speculative demand cycles.

For instance, as global healthcare spending continues to grow at approximately 5% annually, antibiotic procurement expands proportionally. The Lincosamides Market benefits from its entrenched clinical positioning across multiple specialties—dermatology, surgery, orthopedics, dentistry, and general medicine.

Datavagyanik concludes that the Lincosamides Market demonstrates durability rooted in essential therapeutic utility. While stewardship programs and resistance patterns shape prescribing prudence, the core demand drivers—rising infections, expanding procedures, and allergy substitution—ensure sustained relevance across healthcare systems worldwide.

“Track Country-wise Lincosamides Production and Demand through our Lincosamides Production Database”

• • • Lincosamides production database for 22+ countries worldwide
    • Lincosamides sales volume for 22+ countries
    • Country-wise Lincosamides production capacity and production plant mapping, production capacity utilization for 20+ manufacturers
    • Lincosamides production plants and production plant capacity analysis for top manufacturers

Lincosamides Market Geographical Demand Concentrated in North America

The Lincosamides Market demonstrates strong demand concentration in North America, driven by high prescription volumes for skin infections, surgical prophylaxis, and MRSA-related treatments. For instance, the United States performs over 50 million surgical procedures annually, with surgical site infection prevention protocols routinely incorporating clindamycin for penicillin-allergic patients. This alone sustains significant institutional demand within the Lincosamides Market.

Datavagyanik indicates that outpatient antibiotic prescriptions in North America exceed 250 million annually, with dermatology and SSTI-related treatments forming a sizable portion. Acne prevalence among adolescents reaches nearly 85%, while moderate-to-severe cases requiring systemic therapy represent approximately 15–20% of this population. Such figures translate into sustained demand for oral and topical clindamycin formulations. In addition, high MRSA surveillance rates encourage susceptibility-guided prescriptions, further stabilizing the Lincosamides Market in the region.

Lincosamides Market Expansion Across Europe Supported by Stewardship Protocols

The Lincosamides Market in Europe reflects a balanced combination of controlled antibiotic usage and steady clinical demand. Countries such as Germany, France, Italy, and Spain report rising orthopedic and dental procedure volumes, growing at approximately 3–4% annually due to aging demographics. For example, hip replacement procedures in Western Europe are increasing by over 5% annually, reinforcing prophylactic antibiotic consumption.

At the same time, antimicrobial stewardship programs ensure rational prescribing. Rather than reducing demand entirely, stewardship shifts focus toward evidence-based utilization. Clindamycin remains embedded in treatment pathways for anaerobic infections and dental abscesses, supporting consistent procurement volumes. Datavagyanik notes that hospital antibiotic budgets in Western Europe have grown at roughly 2–3% annually, anchoring stable expansion of the Lincosamides Market across institutional channels.

Lincosamides Market Growth Accelerating in Asia-Pacific Healthcare Systems

Asia-Pacific represents the fastest-growing regional contributor to the Lincosamides Market. Healthcare expenditure growth across major economies such as China, India, and Southeast Asian countries averages between 7–10% annually. Rising urbanization, higher infection burden, and improved healthcare access directly influence antibiotic consumption volumes.

For example, India performs more than 30 million surgical procedures annually, while China’s hospital admissions have increased steadily alongside insurance penetration expansion. Dermatology clinics in metropolitan centers are expanding rapidly, with cosmetic dermatology services growing at 8–10% annually. As acne treatment demand increases, oral and topical clindamycin prescriptions follow similar growth trajectories.

Datavagyanik observes that Asia-Pacific now contributes more than one-third of incremental growth in the Lincosamides Market, supported by expanding pharmaceutical manufacturing infrastructure and competitive generic production.

Lincosamides Market Demand Patterns in Latin America and Middle East & Africa

In Latin America, the Lincosamides Market is shaped by public healthcare expansion and rising infectious disease prevalence. Countries such as Brazil and Mexico report consistent growth in outpatient antibiotic usage, particularly for respiratory and skin infections. Urban population density contributes to higher bacterial transmission rates, for instance, increasing SSTI incidence in tropical climates.

Meanwhile, in the Middle East & Africa, healthcare infrastructure investments are accelerating. Gulf countries are expanding tertiary care hospitals, while Sub-Saharan Africa is improving primary healthcare access. As hospital bed capacity increases by approximately 4–6% annually in selected economies, antibiotic procurement volumes expand proportionally, strengthening regional participation in the Lincosamides Market.

Lincosamides Market Production Landscape Dominated by Generic Manufacturing

The production structure of the Lincosamides Market is largely generic and highly decentralized. Active pharmaceutical ingredient (API) manufacturing is concentrated in Asia, particularly in China and India, where cost efficiencies and scale advantages dominate. For instance, India accounts for a substantial share of global generic antibiotic exports, supported by USFDA- and EMA-approved facilities.

Finished dosage manufacturing, including capsules, injectables, and topical formulations, is geographically diversified. North America and Europe maintain strong domestic production for hospital-grade injectables, while Asia-Pacific focuses on high-volume oral and topical generics. Datavagyanik highlights that production capacity expansion in Asia has grown at approximately 6–8% annually, ensuring global supply continuity in the Lincosamides Market.

Lincosamides Market Segmentation by Formulation

The Lincosamides Market can be segmented into oral, injectable, and topical formulations. Oral capsules represent the largest share, accounting for more than 50% of total volume consumption. This dominance stems from outpatient prescriptions for SSTIs and acne management.

Injectable formulations represent approximately 25–30% of revenue contribution, driven by hospital usage in severe infections and surgical prophylaxis. For example, tertiary hospitals maintain higher procurement value per unit for injectables due to sterile production standards. Topical gels and lotions, though smaller in absolute value, are growing steadily at around 5–6% annually, supported by dermatology expansion.

Such segmentation ensures diversified revenue streams within the Lincosamides Market, minimizing overdependence on a single therapeutic setting.

Lincosamides Market Segmentation by Application Area

By application, the Lincosamides Market spans skin and soft tissue infections, bone and joint infections, respiratory infections, dental infections, and acne treatment. Skin infections account for the largest share, contributing nearly 35–40% of total prescriptions. Acne treatment contributes approximately 20–25%, reflecting dermatology-linked outpatient volumes.

Bone and joint infections, while lower in volume, represent higher-value hospital treatments. For instance, osteomyelitis management often involves prolonged antibiotic therapy, increasing cumulative revenue per patient episode. Dental applications also hold strong share due to widespread prophylactic use.

This broad therapeutic coverage stabilizes demand cycles in the Lincosamides Market, ensuring multi-specialty penetration.

Lincosamides Price Influenced by Generic Competition and Tendering

The Lincosamides Price structure is heavily influenced by generic competition. Since clindamycin is off-patent, multiple manufacturers compete across regions. In mature markets, average Lincosamides Price levels have declined modestly by 2–3% annually due to hospital tender systems and pharmacy benefit negotiations.

For example, bulk procurement contracts in public hospital networks can reduce injectable Lincosamides Price by up to 10–15% compared to retail equivalents. However, stable demand ensures that revenue erosion remains contained. Datavagyanik identifies that oral formulations experience greater price competition than injectables due to higher manufacturer participation.

Lincosamides Price Trend Reflecting Regional Variations

The Lincosamides Price Trend varies significantly by geography. In North America and Western Europe, pricing remains relatively stable due to regulatory oversight and reimbursement structures. In contrast, emerging markets display greater price sensitivity. For instance, competitive local manufacturing in India results in lower average Lincosamides Price compared to imported products.

Over the past five years, the global Lincosamides Price Trend has reflected moderate softening in oral generics, while injectable formulations maintain firmer pricing due to higher compliance and sterile manufacturing costs. Datavagyanik notes that raw material costs, particularly fermentation-derived API inputs, influence periodic fluctuations in Lincosamides Price Trend.

Lincosamides Market Resilience Amid Price Pressures

Despite competitive pricing dynamics, the Lincosamides Market maintains revenue resilience. The essential nature of antibiotic therapy limits substitution risk. Even when Lincosamides Price declines in competitive tenders, higher procedure volumes and infection rates offset margin compression.

For example, global healthcare expenditure growth averaging 5% annually supports parallel increases in antibiotic procurement budgets. As surgical volumes and dermatology consultations expand, overall consumption rises. The Lincosamides Price Trend may show incremental downward adjustments in certain generics, yet total market value remains supported by consistent demand elasticity.

“Lincosamides Manufacturing Database, Lincosamides Manufacturing Capacity”

• • • Lincosamides top manufacturers market share for 23+ manufacturers
    • Top 5 manufacturers and top 10 manufacturers of Lincosamides in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Lincosamides production data for 20+ market players
    • Lincosamides production dashboard, Lincosamides production data in excel format

Lincosamides Market Top Manufacturers Driving Global Supply

The Lincosamides Market is led by a concentrated set of pharmaceutical manufacturers with strong capabilities in antibiotic production, generic formulations, and global distribution networks. These companies have developed diverse product portfolios that include oral, injectable, and topical clindamycin formulations. Key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sandoz (Novartis), Sun Pharma, Mylan (Viatris), Cipla Ltd., and Zydus Cadila collectively shape the competitive landscape of the Lincosamides Market. These manufacturers compete on scale, regulatory compliance, product availability, and regional distribution reach.

Pfizer Inc. has maintained a significant presence in the Lincosamides Market through its injectable clindamycin products used extensively in hospital settings. Pfizer’s portfolio includes high-purity sterile injectables designed for severe infections and surgical prophylaxis. The company’s established supply chain across North America and Europe enables consistent institutional procurement, contributing to its dominant position in hospital-grade Lincosamides Market segments.

Teva Pharmaceutical Industries Ltd. is one of the largest generic pharmaceutical manufacturers globally, with a strong footprint in the Lincosamides Market via clindamycin capsules and topical gels. Teva’s generic oral products are widely distributed across both developed and emerging markets. The company’s ability to leverage high-volume manufacturing infrastructure allows competitive pricing, particularly in price-sensitive regions such as Latin America and Asia-Pacific.

Lincosamides Market Share by Leading Pharma Companies

The Lincosamides Market share is divided among major global and regional manufacturers, with generics commanding the largest portion of total volume. Teva, Sandoz, Mylan (Viatris), and Sun Pharma collectively account for a significant majority—estimated between 40–50%—of the total global Lincosamides Market share in terms of volume. This dominance stems from their extensive oral and topical product portfolios tailored to outpatient and retail channels.

Pfizer’s market share, while comparatively smaller in overall volume, holds greater value in hospital injectable segments. For example, injectable clindamycin products contribute disproportionately higher revenue per unit compared to oral capsules. Thus, Pfizer’s contribution to value share in the Lincosamides Market remains considerable.

In contrast, regional manufacturers such as Cipla Ltd. and Zydus Cadila consolidate strong positions within Asia-Pacific and select emerging markets. Their localized supply chains and regulatory registrations support significant market penetration. Cipla’s branded and generic clindamycin products are widely distributed within hospital and pharmacy networks across India, Africa, and parts of the Middle East. Zydus Cadila’s focus on dermatological formulations, including combination topical therapies, further broadens its participation in the Lincosamides Market.

Sandoz and Mylan (Viatris) Enhancing Generic Lincosamides Market Accessibility

Sandoz, a division of Novartis specializing in generics, holds a substantive share in the Lincosamides Market through cost-efficient oral and topical offerings. Sandoz’s global distribution channels span Europe, North America, and Asia-Pacific, enabling widespread adoption of its clindamycin formulations. The company’s strategic partnerships with contract manufacturers facilitate agility in production scaling, aligning supply with demand trends.

Mylan, now part of Viatris following corporate consolidation, also retains a sizeable share of the Lincosamides Market. Mylan’s portfolio includes clindamycin capsules widely prescribed for SSTIs and acne, as well as branded generics in select markets where regulatory exclusivities persist. Viatris’ consolidated global reach broadens accessibility of these products, particularly in markets with high outpatient antibiotic consumption.

Sun Pharma’s Strategic Position in Emerging Markets

Sun Pharma commands a leading share of the Lincosamides Market in India and neighboring regions, supported by extensive manufacturing capacity and a diverse antibiotic portfolio. Its clindamycin oral and topical formulations are frequently stocked in retail pharmacies and hospital formularies. For example, Sun Pharma’s branded clindamycin products enjoy strong brand recognition among clinicians and patients, contributing to robust market share in dermatology and general practice settings.

The company’s sustained investment in quality control and regulatory compliance enables distribution to regulated markets, including parts of Europe and Africa. Datavagyanik notes that in regions with expanding healthcare access, Sun Pharma’s market share continues to grow in direct proportion to rising outpatient prescription volumes.

Emerging Manufacturers in the Lincosamides Market

While major global players hold the largest shares, emerging manufacturers are gaining traction in niche segments of the Lincosamides Market. Companies such as Alkem Laboratories, Glenmark Pharmaceuticals, Hetero Drugs, and Fresenius Kabi have developed targeted portfolios focusing on topical formulations, hospital injectable products, and regional distribution networks.

For instance, Fresenius Kabi’s sterile injectable antibiotics, including clindamycin, cater specifically to hospital pharmacies and critical care units. Though smaller in overall market share compared to Pfizer and Teva, Fresenius Kabi’s specialization in high-quality sterile manufacturing supports steady growth in its segment.

Similarly, Alkem Laboratories and Glenmark Pharmaceuticals have expanded their dermatological clindamycin products, aligning with growing outpatient demand in Asia-Pacific and Latin America. These emerging companies collectively augment competitive intensity within the Lincosamides Market by addressing specific regional and therapeutic niches.

Lincosamides Market Share Dynamics by Product Line

The Lincosamides Market share varies significantly by product line. Oral capsules represent the highest volume segment, capturing an estimated 55–60% of total consumption. Within this category, generic manufacturers such as Teva, Sandoz, Mylan, and Sun Pharma dominate due to broader distribution and cost competitiveness.

Injectable clindamycin products hold approximately 25–30% of revenue share, driven by hospital usage. Pfizer and Fresenius Kabi lead this segment, supported by robust sterile manufacturing capacities and long-term contracts with institutional buyers.

Topical formulations account for roughly 15–20% of the Lincosamides Market share. Here, dermatology-focused products—including clindamycin gels and combination therapies—gain traction. Companies such as Cipla, Zydus Cadila, and Glenmark Pharmaceuticals have strengthened presence in this niche, competing on formulation quality and brand recognition.

Strategic Market Share Shifts Driven by Regional Demand

Regional demand dynamics significantly shape manufacturer market share within the Lincosamides Market. In North America and Western Europe, large multinational companies with established regulatory footprints—such as Pfizer, Teva, and Sandoz—capture the lion’s share due to trusted product lines and compliance with stringent quality standards.

Conversely, in Asia-Pacific, Latin America, and select Middle East regions, regional manufacturers have increased their market share by capitalizing on localized distribution, tailored product portfolios, and competitive pricing. For example, Cipla and Sun Pharma lead in India and parts of Africa, supported by strong relationships with public and private healthcare networks.

Datavagyanik observes that as healthcare systems in emerging markets expand, regional manufacturers will continue to capture incremental market share within the Lincosamides Market, particularly in outpatient and retail segments.

Recent News and Industry Developments in the Lincosamides Market

December 2025 – Expansion of Sterile Injectable Capacity: A leading pharmaceutical manufacturer announced expansion of sterile injectable antibiotic production lines, including clindamycin injectables, aimed at strengthening supply to North American and European hospital systems. The new facility is scheduled to come online by Q3 2026, addressing rising demand for high-quality hospital antibiotics.

October 2025 – Strategic Distribution Partnership: A global generics manufacturer entered into a strategic distribution partnership with a regional pharmaceutical distributor in Latin America to expand clindamycin product penetration across pharmacy networks. This partnership is expected to boost the company’s Lincosamides Market share in key urban centers by mid-2026.

August 2025 – Dermatology Portfolio Launch: A mid-sized pharmaceutical firm launched an enhanced topical clindamycin gel formulation with improved skin delivery technology. Early adoption among dermatologists in Asia-Pacific suggests potential for rapid uptake, supporting expanded participation in the topical segment of the Lincosamides Market.

June 2025 – Price Stability Initiatives: Several major manufacturers agreed on industry-wide quality benchmarks aimed at stabilizing Lincosamides Price trends amid intense competition. By harmonizing quality standards and ensuring reliable supply chains, these initiatives aim to reduce pricing volatility in oral and injectable clindamycin products.

These developments reflect the ongoing evolution of the Lincosamides Market. Competitive positioning, strategic investments, and regional demand shifts continue to influence market share dynamics. As manufacturers adapt portfolios and expand capabilities, the competitive landscape remains dynamic, with opportunities for growth across multiple segments and geographies.

“Lincosamides Production Data and Lincosamides Production Trend, Lincosamides Production Database and forecast”

• • • Lincosamides production database for historical years, 12 years historical data
    • Lincosamides production data and forecast for next 8 years